» Articles » PMID: 21769491

ISN/RPS 2003 Class II Mesangial Proliferative Lupus Nephritis: a Comparison Between Cases That Progressed to Class III or IV and Cases That Did Not

Overview
Journal Rheumatol Int
Specialty Rheumatology
Date 2011 Jul 20
PMID 21769491
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Lupus nephritis (LN) class II has generally been considered a mild form of LN with a good response to treatment. Although the number was small, there have also been reports on later progression to class III or IV, resulting in poor renal and patient outcome. This study aims to review cases of LN class II to analyze differences between cases that progressed to class III or IV and cases that did not. We retrospectively analyzed 15 cases of LN class II among 277 cases of biopsy-proven lupus nephritis diagnosed in a tertiary medical center over about 14 years. Among the 15 patients, 5 patients progressed to class III or IV. Biopsy specimens were reviewed by a pathologist according to the ISN/RPS 2003 classification. Response to treatment was evaluated at 6 months after treatment. On fluorescence microscopy (IF), there was significantly higher degree of deposition in the glomeruli of IgM, IgA and C4 in the progression group than in the non-progression group. At 6 months after treatment, there was a trend toward higher rates of complete remission in the non-progression group (90%) compared with those in the progression group (40%, p = 0.077). Five of the 15 cases of ISN/RPS 2003 class II glomerulonephritis progressed to class III or IV over a mean of 5 years. The degree of immune-complex deposition for IgM, IgA and C4 in the glomeruli was significantly higher in the progression group.

Citing Articles

Molecular signatures of intrarenal complement receptors and correlate with renal outcome in human lupus nephritis.

Tampe D, Hakroush S, Tampe B Lupus Sci Med. 2022; 9(1).

PMID: 36521939 PMC: 9756185. DOI: 10.1136/lupus-2022-000831.


2020 Chinese Guidelines for the Diagnosis and Treatment of Systemic Lupus Erythematosus.

Li M, Zhao Y, Zhang Z, Huang C, Liu Y, Gu J Rheumatol Immunol Res. 2022; 1(1):5-23.

PMID: 36465077 PMC: 9524765. DOI: 10.2478/rir-2020-0009.


Long-term renal outcomes of mesangial proliferative lupus nephritis in Chinese patients.

Wang S, Chen D, Zuo K, Xu F, Hu W Clin Rheumatol. 2021; 41(2):429-436.

PMID: 34549340 DOI: 10.1007/s10067-021-05909-y.


Lupus nephritis: clinical presentations and outcomes in the 21st century.

Gasparotto M, Gatto M, Binda V, Doria A, Moroni G Rheumatology (Oxford). 2020; 59(Suppl5):v39-v51.

PMID: 33280015 PMC: 7751166. DOI: 10.1093/rheumatology/keaa381.


[Lupus nephritis].

Melderis S, Wiech T, Iking-Konert C, Steinmetz O Z Rheumatol. 2018; 77(7):593-608.

PMID: 29955955 DOI: 10.1007/s00393-018-0496-4.


References
1.
Ginzler E, NICASTRI A, Chen C, Friedman E, Diamond H, KAPLAN D . Progression of mesangial and focal to diffuse lupus nephritis. N Engl J Med. 1974; 291(14):693-6. DOI: 10.1056/NEJM197410032911402. View

2.
Hill G, Delahousse M, Nochy D, Bariety J . Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int. 2005; 68(5):2288-97. DOI: 10.1111/j.1523-1755.2005.00688.x. View

3.
Appel G, Cohen D, PIRANI C, Meltzer J, Estes D . Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med. 1987; 83(5):877-85. DOI: 10.1016/0002-9343(87)90645-0. View

4.
Faurschou M, Starklint H, Halberg P, Jacobsen S . Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006; 33(8):1563-9. View

5.
Furness P, Taub N . Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study. Am J Surg Pathol. 2006; 30(8):1030-5. DOI: 10.1097/00000478-200608000-00015. View